Form 4: Vertex CSO Sells Shares, Acquires RSUs Under 10b5-1 Plan

Vertex Pharmaceuticals' Chief Scientific Officer, Mark E. Bunnage, reported the acquisition of restricted stock units and subsequent sales of common stock under a pre-arranged trading plan.

Summary

• Mark E. Bunnage, Executive Vice President and Chief Scientific Officer of Vertex Pharmaceuticals Inc. (VRTX), reported transactions involving the company's common stock.
• On February 17, 2026, Mr. Bunnage acquired 2,584 shares of common stock as a restricted stock unit (RSU) award, with a price of $0.
• These restricted stock units are scheduled to vest in installments beginning on February 20, 2027.
• Also on February 17, 2026, Mr. Bunnage disposed of 1,110 shares of common stock at a price of $483.75, likely for tax withholding purposes related to the vesting of other awards.
• On February 17, 2026, Mr. Bunnage sold 2,437 shares of common stock at an average price of $489.46.
• On February 18, 2026, Mr. Bunnage sold an additional 1,182 shares of common stock at an average price of $473.68.
• All disposition transactions (sales and tax withholding) were made pursuant to a Rule 10b5-1 trading plan, which Mr. Bunnage entered into on November 26, 2025.
• Following these reported transactions, Mr. Bunnage beneficially owns 8,486 shares of Vertex Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The acquisition of new restricted stock units is balanced by sales under a pre-arranged 10b5-1 plan, which are generally considered routine and not indicative of new insider sentiment.

Positives

• The acquisition of 2,584 restricted stock units (RSUs) indicates continued equity-based compensation for the Chief Scientific Officer, aligning his interests with long-term company performance.

Negatives

• Mr. Bunnage disposed of a net total of 4,729 shares (1,110 for tax withholding and 3,619 through sales) over two days, reducing his direct beneficial ownership.

Future Outlook

The acquired restricted stock units are scheduled to vest in installments starting on February 20, 2027, indicating future equity compensation for the Chief Scientific Officer.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those involving the acquisition of equity awards and subsequent sales under pre-arranged 10b5-1 plans, are common practices in the pharmaceutical industry for executive compensation, liquidity management, and tax planning. These routine transactions typically do not signal a change in company fundamentals.

Stakeholder Impact

• Shareholders may observe a net reduction in the Chief Scientific Officer's direct beneficial ownership, but the pre-arranged nature of the sales under a 10b5-1 plan suggests these are not based on new, non-public information.

Next Steps

• The restricted stock units acquired on February 17, 2026, will begin to vest in installments starting on February 20, 2027.

Key Dates

Recommendation

The Form 4 details routine insider transactions, including the acquisition of restricted stock units and subsequent sales under a pre-arranged 10b5-1 plan. These transactions do not provide new fundamental information to warrant a change in investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

VRTX, Vertex Pharmaceuticals, Insider Transaction, Form 4, Stock Sale, RSU Award, Executive Compensation, 10b5-1 Plan